(Rettsyndrome.org) The International Rett Syndrome Foundation, now doing business as Rettsyndrome.org, announces today that Neuren Pharmaceuticals reported that trofinetide had significant clinical benefit in their Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15. Rettsyndrome.org (a sponsor of this trial) is enthusiastic about the results and proud to partner with Neuren to move trofinetide forward toward the Phase 3 clinical trial.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2mUz3Ox
No comments:
Post a Comment